SCHEDULE OF SEGMENT REPORTING (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Revenues	$ 18	$ 286
Operating Expenses	28,530	27,494
(Loss) Income from Operations	(28,512)	(27,265)
Total Assets	1,798	4,110
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenues	18	286
Operating Expenses	29,238	26,819
(Loss) Income from Operations	(29,265)	(26,590)
Total Assets	485	4,051
Viral Clear Pharmaceuticals Inc [Member]
Segment Reporting Information [Line Items]
Revenues
Operating Expenses	(1,498)	672
(Loss) Income from Operations	1,498	(672)
Total Assets		49
BioSig AI Sciences Inc [Member]
Segment Reporting Information [Line Items]
Revenues
Operating Expenses	745	3
(Loss) Income from Operations	(745)	(3)
Total Assets	$ 1,313	$ 10